FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office
Jacqueline Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.
You may also be interested in...
Jacqueline Corrigan-Curay brings a broad array of policy experience, from trial design to real-world evidence to supply chain and post-market surveillance, to the CDER principal deputy director role, though US FDA is not yet able to articulate exactly what her promotion will entail.
Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.
Peter Stein, a leader in diabetes drug development programs, joins FDA as a new administration is about to come in; he fills one of 676 CDER vacancies.